TENX

Business Context and Reporting Period

Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended October 31, 2005 (Form 10-Q).
Business Stage: Development stage company focused on perfluorocarbon-based medical products, primarily "Oxycyte" (a synthetic blood substitute) and "Fluorovent" (an oxygen exchange fluid). The company also pursues a glucose biosensor implant.
Going Concern: The filing states substantial doubt exists regarding the company's ability to continue as a going concern due to an accumulated deficit of $25.9 million and reliance on future financing to fund clinical trials.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the three months ended Oct 31, 2005, increased to $1.68 million from $600,000 in the prior year period. The six-month loss increased to $2.29 million from $1.07 million.
• Interest Expense Spike: Interest expense increased by $1,016,652 in the current quarter due to the accelerated conversion of convertible notes payable and amortization of discounts (original issue discount, warrant value, and beneficial conversion features).
• Expense Growth: General and Administrative (G&A) expenses rose due to increased investor relations costs ($60,000 for the quarter) and a write-off of $34,205 related to the termination of a patent agreement.
• Financing Activity: In July 2005, the company issued approximately $1.85 million in convertible debentures, netting approximately $1.13 million in proceeds. Investors subsequently converted $813,357 of these debentures into common stock during the quarter.

Guidance, Outlook, and Risks

• Clinical Trial Status: Phase II enrollment for Oxycyte in orthopedic surgery was temporarily halted due to slower-than-expected patient enrollment (11 patients enrolled). New Phase II trials for brain ischemia and sickle cell crisis are expected to begin in December 2005, with results anticipated in early 2006.
• Liquidity Outlook: Management believes current cash ($712,047) plus recent financing will fund operations until the first quarter of 2006. The company estimates Phase II trial costs for 2005 and 2006 at $8 million.
• Capital Needs: The company faces significant difficulty raising additional capital. Continued operations beyond late 2005 depend entirely on securing outside financing or strategic alliances.
• Accounting Changes: The company currently uses APB Opinion No. 25 for stock-based compensation. Adoption of SFAS No. 123(R) is required by May 1, 2006, which is expected to increase non-cash stock-based compensation charges.
• Risks: Substantial doubt about going concern status; reliance on FDA approval for products in pre-clinical/clinical stages; potential dilution from convertible debt and warrants.

Investor Verification Checklist

• Capital Runway: Verify if the company has secured funding beyond the projected first quarter of 2006 cutoff.
• Clinical Enrollment: Monitor the status of the paused orthopedic Phase II trial and the start dates for the new brain ischemia and sickle cell trials.
• Dilution Impact: Assess the impact of the $1.85 million convertible debentures and associated warrants (8.4 million shares) on future share count.
• Going Concern: Review subsequent filings for any updates on the "substantial doubt" regarding the company's ability to continue operations.
• Related Party Transactions: Note payments to a specialty contract manufacturer where an officer is a minority shareholder/director.